Morningstar, Inc. (NASDAQ:MORN – Get Free Report) Chairman Joseph D. Mansueto sold 9,062 shares of the business’s stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $328.22, for a total transaction of $2,974,329.64. Following the transaction, the chairman now directly owns 10,845,718 shares of the company’s stock, valued at $3,559,781,561.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.
Morningstar Price Performance
NASDAQ:MORN traded up $2.32 during midday trading on Monday, hitting $330.73. 140,572 shares of the stock were exchanged, compared to its average volume of 115,621. The company has a market capitalization of $14.18 billion, a price-to-earnings ratio of 43.38 and a beta of 1.18. The company has a current ratio of 1.14, a quick ratio of 1.05 and a debt-to-equity ratio of 0.55. Morningstar, Inc. has a one year low of $259.50 and a one year high of $349.07. The business has a 50-day moving average price of $323.12 and a two-hundred day moving average price of $308.13.
Morningstar (NASDAQ:MORN – Get Free Report) last posted its quarterly earnings data on Wednesday, October 23rd. The business services provider reported $2.00 EPS for the quarter, missing analysts’ consensus estimates of $2.01 by ($0.01). Morningstar had a return on equity of 23.28% and a net margin of 14.69%. The firm had revenue of $569.40 million during the quarter.
Morningstar Dividend Announcement
Analysts Set New Price Targets
A number of research firms have recently weighed in on MORN. Redburn Atlantic cut Morningstar from a “buy” rating to a “neutral” rating and set a $340.00 price target on the stock. in a report on Wednesday, October 9th. UBS Group started coverage on Morningstar in a research note on Tuesday, October 8th. They set a “buy” rating and a $390.00 target price on the stock. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $352.00 price target on shares of Morningstar in a research report on Wednesday, August 28th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, Morningstar presently has an average rating of “Moderate Buy” and a consensus price target of $360.67.
View Our Latest Research Report on Morningstar
Institutional Trading of Morningstar
A number of hedge funds and other institutional investors have recently made changes to their positions in MORN. V Square Quantitative Management LLC purchased a new stake in shares of Morningstar in the 3rd quarter valued at approximately $30,000. Blue Trust Inc. grew its position in Morningstar by 326.9% during the 2nd quarter. Blue Trust Inc. now owns 111 shares of the business services provider’s stock worth $34,000 after purchasing an additional 85 shares in the last quarter. Crewe Advisors LLC acquired a new stake in Morningstar during the 2nd quarter valued at $35,000. DT Investment Partners LLC acquired a new stake in shares of Morningstar in the second quarter worth $36,000. Finally, Acadian Asset Management LLC grew its holdings in shares of Morningstar by 73.8% during the second quarter. Acadian Asset Management LLC now owns 146 shares of the business services provider’s stock valued at $43,000 after buying an additional 62 shares in the last quarter. 57.02% of the stock is currently owned by institutional investors.
Morningstar Company Profile
Morningstar, Inc provides independent investment insights in the United States, Asia. Australia, Continental Europe, the United Kingdom, and internationally. The company operates in five segments: Morningstar Data and Analytics; PitchBook; Morningstar Wealth; Morningstar Credit; and Morningstar Retirement.
Featured Stories
- Five stocks we like better than Morningstar
- What Makes a Stock a Good Dividend Stock?
- Intel: Is Now the Time to Be Brave?Â
- Stock Market Upgrades: What Are They?
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Morningstar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morningstar and related companies with MarketBeat.com's FREE daily email newsletter.